← All organizations
Highest phase reached
Phase 3
First clinical trial
May 24, 2001Last known activity
Aug 3, 2021
Timeline
1950s
- Jan 1, 1955
Zeria Pharmaceutical— Founded
2000s
- Jan 1, 2009
Tillotts Pharma (1999)— Acquired
Drugs by trial phase (11 distinct, 25 trials)
Phase 3 (7 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Adenocarcinoma
- Anemia
- Anemia, Iron-Deficiency
- Carcinoma
- Carcinoma, Hepatocellular
- Colitis
- Colitis, Ulcerative
- Communicable Diseases
- Deficiency Diseases
- Dyspepsia
- Esophagitis
- Esophagitis, Peptic
- Familial Hypophosphatemic Rickets
- HIV Infections
- Hyperkalemia
- Infections
- Pancreatic Neoplasms
- Rickets
- Rickets, Hypophosphatemic
- Ulcer
- Uterine Cervical Neoplasms
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (28)
- NCT04955678Study directorPhase 3Aug 3, 2021
- NCT04955678Lead sponsorPhase 3Aug 3, 2021
- NCT04526119Study directorPhase 3Feb 22, 2021
- NCT04526119Lead sponsorPhase 3Feb 22, 2021
- NCT03799926Lead sponsorPhase 2Jan 31, 2019
- NCT03476018Lead sponsorPhase 3Apr 2, 2018
- NCT02828319Lead sponsorPhase 3Jul 1, 2016
- NCT02731534Lead sponsorPhase 3May 1, 2016
- NCT02618629Lead sponsorPhase 1Jan 1, 2016
- NCT02509923Lead sponsorPhase 1Jul 1, 2015
- NCT02463643Lead sponsorPhase 2May 1, 2015
- NCT02247232Lead sponsorPhase 3Dec 1, 2014
- NCT02170311Lead sponsorPhase 1Jun 1, 2014
- NCT02170311Study directorPhase 1Jun 1, 2014
- NCT02117258Lead sponsorPhase 2Apr 1, 2014
Details
- Founded
- Tokyo, JP Jan 1, 1955
- Last known activity
- Aug 3, 2021